Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Superfractionation in glioblastoma multiforme--Results of a phase II study

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
 [1];
  1. Cancer Control Agency of British Columbia, Vancouver, Canada

A sequential series of 30 patients who were referred to a cancer treatment hospital with glioblastoma multiforme were treated with superfractionated cobalt 60 ..gamma.. radiation, three treatments per day, 100 rad per fraction. Their survival was compared to that of a historical group of 90 patients who had been referred for the same disease. Survival of the study patients was significantly longer than the historical patients, both for those who underwent resection (48.6 weeks median survival vs. 35.1 weeks), and for those who did not (35.1 weeks vs 11.7 weeks). A retrospective survey of the historical group led to the following conclusions about this group: 1. Survival for patients who were well enough to be referred was unchanged after steroids came into general use; 2. Younger patients (under 50 years) did not have a longer survival than older patients; 3. The size of the dose of irradiation did not affect survival over the range of doses employed; 4. The size of the treatment volume employed did not affect survival over the range of treatment volumes employed.

OSTI ID:
6941314
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 8:10; ISSN IOBPD
Country of Publication:
United States
Language:
English